Literature DB >> 15483466

Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection.

Dawn A Fishbein1, Yungtai Lo, John F Reinus, Marc N Gourevitch, Robert S Klein.   

Abstract

The objective of this study was to determine outcomes of referring drug users (DUs) with chronic hepatitis C for clinical evaluation and care. Two hundred twenty-eight persons with detectable hepatitis C virus RNA were given expedited referrals for evaluation and possible treatment of hepatitis C from a prospective study cohort of current and former opiate-addicted DUs. Four outcomes were analyzed: accepted referral, arrived for clinical evaluation, had liver biopsy, and received treatment. One hundred twenty-seven participants (56%) accepted referral, of whom 54 (43%) arrived for evaluation. Of these participants, 12 (22%) had liver biopsy, and 4 (7%) were treated. Multivariate logistic regression revealed that HIV-infected DUs were significantly less likely to accept referral (adjusted odds ratio [O(Radj)], 0.51; 95% confidence interval [CI], 0.30-0.88), and older participants were more likely to keep an appointment (O(Radj), 1.06/y; 95% CI, 1.00-1.12). Of HIV-seropositive participants, those with a history of injection were more likely to accept referral (O(Radj), 3.60; 95% CI, 1.08-11.96), and those with higher HIV load (O(Radj), 0.50/log10; 95% CI, 0.26-0.94) and Hispanic ethnicity (O(Radj), 0.26; 95% CI, 0.07-0.89) were less likely to keep an appointment. Despite expedited referrals for hepatitis C care, only a few participants received an evaluation, and even far fewer were treated. Because increasingly effective treatment is available, better methods are urgently needed to improve evaluation and treatment of HCV-infected DUs, including those coinfected with HIV.

Entities:  

Mesh:

Year:  2004        PMID: 15483466     DOI: 10.1097/01.qai.0000131932.21612.49

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  The beginning of a new era in understanding hepatitis C virus prevention.

Authors:  Josiah D Rich; Lynn E Taylor
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

2.  Managing chronic hepatitis C in primary-care settings: more than antiviral therapy.

Authors:  Barry Zevin
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

3.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

4.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

5.  A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

Authors:  Diane S Morse; Miriam Schiff; Shabtay Levit; Rinat Cohen-Moreno; Geoffrey C Williams; Yehuda Neumark
Journal:  Subst Use Misuse       Date:  2012-01       Impact factor: 2.164

6.  Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.

Authors:  Lynn E Taylor; Sarah E Bowman; Stacey Chapman; Nickolas Zaller; Michael D Stein; Patricia A Cioe; Michaela A Maynard; Barbara Hedgis McGovern
Journal:  Drug Alcohol Depend       Date:  2010-12-21       Impact factor: 4.492

7.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

8.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

9.  A comparison of modified directly observed therapy to standard care for chronic hepatitis C.

Authors:  Patricia A Cioe; Michael D Stein; Kittichai Promrat; Peter D Friedmann
Journal:  J Community Health       Date:  2013-08

10.  Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

Authors:  J Grebely; K Petoumenos; G V Matthews; P Haber; P Marks; A R Lloyd; J M Kaldor; G J Dore; M Hellard
Journal:  Drug Alcohol Depend       Date:  2010-03-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.